Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 3,107 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment of depression Clear all

Conditions: Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions: cisplatin, fluoxetine, gemcitabine hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 42
States / cities: Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more

Conditions: Chronic Low Back Pain, Negative Affectivity
Interventions: Antidepressant, Enhanced Fear Avoidance Rehabilitation; Drug · Other
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Depression
Interventions: Intermittent Theta Burst Stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anhedonia, Emotional Blunting
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Behavioral Activation, Exercise Intervention, Stretching Intervention; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sexual Violence
Interventions: RealConsent, Stress and Mood Management; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years to 20 Years · Female only
Enrollment: 881 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions: Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 35 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Knee Pain Chronic
Interventions: transcranial direct current stimulation, physical therapy; Device · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions: MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation; Device · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 25 Years to 64 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions: Citicoline, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: SAINT® Neuromodulation System (NMS); Device
Lead sponsor: Magnus Medical; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more

Conditions: Depression in Adolescence, Suicide Prevention
Interventions: Strategic Treatment Assessment for Youth (STAY), Measurement Based Care As Usual; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 12 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment
Interventions: Minds and Mentors, Twelve Step Intervention Group; Behavioral
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 19 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Mental Health Wellness 1
Interventions: Trauma-Sensitive Yoga + TAU, Chen Style Tai Chi + TAU, Treatment as Usual; Behavioral
Lead sponsor: University of Northern Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cedar Falls, Iowa

Conditions: Depressive Disorder, Major
Interventions: electronic diary, Sertraline, Placebo, voice acoustics; Procedure · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Norwich, Connecticut • Aventura, Florida • Jacksonville, Florida + 7 more

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase; Device · Other
Lead sponsor: Wayne Goodman MD; Other
Eligibility: 21 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postpartum Depression (PPD), Alcohol Use, Contingency Management, Problem Solving Therapy
Interventions: Contingency Management & Problem Solving Therapy, Usual Care; Behavioral · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder, Depression
Interventions: ezogabine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Ketamine, Clonidine, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bipolar Disorder
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder, Healthy Volunteer
Interventions: Basimglurant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Alcohol Use Disorder, Substance Use Disorders
Interventions: Measurement, Feedback; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sleep Disturbances, Depression
Interventions: High Active intervention, Inactive intervention, Mid Level Active Intervention; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 65 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Albany, New York • New York, New York

Conditions: Postpartum Depression
Interventions: Placebo, SAGE-547 90 μg/kg/h; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 32
States / cities: Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more

Search by objective public record fields.

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Treating Negative Affect in Low Back Pain Patients

iTBS in Refractory Pediatric Depression

Psilocybin as a Novel Therapy for Residual Anhedonia

Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression

Efficacy of a Web-based Sexual Violence Risk Reduction Program for Female College Students

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

Transcranial Direct Current Stimulation in Conjunction With Individualized Physical Therapy for Individuals With Chronic Knee Pain

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

Open Label Optimization Study

Strategic Treatment and Assessment for Youth (STAY)

Minds and Mentors Program- R33

The Effects of Trauma-sensitive Yoga and Tai Chi on Mental Health

Study for Evaluating Different Methods of Measuring Depression Treatment Response

DBS of the Lateral Habenula in Treatment-Resistant Depression

Maternal Outcomes: Mood, Alcohol Use, and Depressive Symptoms

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Treatment Resistant Depression (Pilot)

Research Study of Bipolar Mood Symptoms and Cognitive Problems

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Addiction Treatment Outcome Monitoring Study

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)